NCT06710665 Tumor Regression Grade As Predictor of Adjuvant Therapy
| NCT ID | NCT06710665 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fujian Medical University Union Hospital |
| Condition | Esophageal Squamous Cell Carcinoma (ESCC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2025-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2024-10-01 with a primary completion date of 2025-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Neoadjuvant therapy followed by surgery is preferred for locally advanced esophageal squamous cell carcinoma, but the necessity of adjuvant therapy remains controversial. Tumor regression grade reflects the response to neoadjuvant therapy and may predict patient prognosis, yet its role in guiding adjuvant therapy remains unexplored.
Eligibility Criteria
Inclusion Criteria: (I) underwent R0 resection with either two-field or three-field lymphadenectomy (II) received neoadjuvant therapy such as preoperative radiotherapy, chemoradiotherapy, or combined immunotherapy (III) had esophageal squamous cell carcinoma pathology. Exclusion Criteria: (I) Patients with incomplete clinical data or follow-up information (II) Diagnosed with multiple primary malignancies
Contact & Investigator
Bin Zheng
STUDY DIRECTOR
Key Laboratory of Cardio-Thoracic Surgery, Fujian Medical University, Fujian Province University, Fu
Frequently Asked Questions
Who can join the NCT06710665 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Esophageal Squamous Cell Carcinoma (ESCC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06710665 currently recruiting?
Yes, NCT06710665 is actively recruiting participants. Contact the research team at 757860733@qq.com for enrollment information.
Where is the NCT06710665 trial being conducted?
This trial is being conducted at Fuzhou, China.
Who is sponsoring the NCT06710665 clinical trial?
NCT06710665 is sponsored by Fujian Medical University Union Hospital. The principal investigator is Bin Zheng at Key Laboratory of Cardio-Thoracic Surgery, Fujian Medical University, Fujian Province University, Fu. The trial plans to enroll 400 participants.